A 40-week Open-Label Extension Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Phase of Trial: Phase III
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Cyclobenzaprine (Primary)
- Indications Post-traumatic stress disorders
- Focus Adverse reactions; Registrational
- Sponsors Tonix Pharmaceuticals Inc
- 30 Sep 2019 Status changed from recruiting to completed.
- 05 Jun 2018 Status changed from not yet recruiting to recruiting.
- 30 Apr 2018 New trial record